AMENDMENT NO. 3 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 16th, 2017 • Argos Therapeutics Inc • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment”) to the Fifth Amended and Restated Registration Rights Agreement, dated August 9, 2013 (the “Registration Rights Agreement”), by and among the Company and the Holders (as defined therein) is entered into as of the 6th day of March, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the signatories hereto. Capitalized terms not defined herein shall have the meanings given to such terms in the Registration Rights Agreement.
LEASE TERM SHEETLease Agreement • March 16th, 2017 • Argos Therapeutics Inc • Pharmaceutical preparations
THIS LEASE TERM SHEET is made a part of the attached Lease Agreement between Landlord and Tenant. Use of the following capitalized terms (indicated in bold type) in this Lease shall be deemed a reference to the information set out below.
SECOND AMENDMENTDevelopment Agreement • March 16th, 2017 • Argos Therapeutics Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO DEVELOPMENT AGREEMENT (the “Second Amendment”) is entered into by and between SAINT-GOBAIN PERFORMANCE PLASTICS CORPORATION, a California corporation having an office at 31500 Solon Road, Solon, OH 44139 (“SGPPL”), and ARGOS THERAPEUTICS, INC., a Delaware corporation having an office at 4233 Technology Drive, Durham, NC 27704 (“Argos”). SGPPL and Argos are hereafter referred to collectively as the “Parties,” “Other Party,” or individually as a “Party”, as applicable.
